Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
July 07 2021 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company
developing innovative therapeutics to treat life-threatening
diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief
Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
Chief Medical Officer of Aravive, will participate in a virtual
fireside chat at the 2021 William Blair Biotech Focus Conference on
July 15, 2021, at 3:00 PM ET. Aravive will also be participating in
one-on-one meetings at the conference.
This meeting is being held virtually, and a live webcast will be
accessible on the Events & Presentations
page of https://aravive.com/. Archived replays of the
webcasts will be available for 90 days following the
presentations.
About AraviveAravive, Inc. is a
clinical-stage oncology company developing innovative therapeutics
to treat life-threatening diseases. Aravive’s lead therapeutic,
AVB-500, is a first-in-class ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor cell
growth, tumor metastasis, resistance to treatment and decreased
survival. AVB-500 has the potential to be combined with multiple
anti-cancer therapies across several tumor types, due to its novel
mechanism of action and favorable safety profile. AVB-500 has been
granted Fast Track Designation by the U.S. Food and Drug
Administration in platinum resistant recurrent ovarian cancer. The
Company is currently evaluating AVB-500 in a registrational Phase 3
trial in platinum resistant ovarian cancer and a Phase 1b/2 trial
in clear cell renal cell carcinoma. Aravive plans to initiate a
Phase 1b/2 trial evaluating AVB-500 in first-line treatment of
pancreatic cancer in the second half of 2021. The Company is based
in Houston, Texas and received a Product Development Award from the
Cancer Prevention & Research Institute of Texas (CPRIT) in
2016. For more information, please visit www.aravive.com.
Contact:Joseph T. SchepersVP, Investor
Relations, Aravive, Inc.jschepers@aravive.com(770) 558-5517
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024